Perkins Coie Trust Co Boosts Stake in Allergan plc (NYSE:AGN)

Perkins Coie Trust Co grew its stake in shares of Allergan plc (NYSE:AGN) by 3,303.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,021 shares of the company’s stock after buying an additional 991 shares during the quarter. Perkins Coie Trust Co’s holdings in Allergan were worth $172,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Liberty Wealth Management LLC boosted its stake in shares of Allergan by 35.3% during the 2nd quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after purchasing an additional 67 shares in the last quarter. TRUE Private Wealth Advisors boosted its stake in shares of Allergan by 4.5% during the 3rd quarter. TRUE Private Wealth Advisors now owns 1,715 shares of the company’s stock valued at $288,000 after purchasing an additional 74 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Allergan by 43.1% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock valued at $44,000 after purchasing an additional 78 shares in the last quarter. Old North State Trust LLC boosted its stake in shares of Allergan by 172.4% during the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock valued at $27,000 after purchasing an additional 100 shares in the last quarter. Finally, YorkBridge Wealth Partners LLC boosted its stake in Allergan by 14.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 812 shares of the company’s stock worth $136,000 after acquiring an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 80.47% of the company’s stock.

Allergan stock traded up $1.17 during trading hours on Friday, hitting $169.00. The stock had a trading volume of 628,090 shares, compared to its average volume of 2,651,670. The company has a quick ratio of 0.91, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $54.81 billion, a P/E ratio of 10.13, a price-to-earnings-growth ratio of 1.98 and a beta of 1.65. Allergan plc has a 12-month low of $114.27 and a 12-month high of $192.69. The stock’s 50-day moving average price is $164.51 and its 200-day moving average price is $151.59.

Allergan (NYSE:AGN) last issued its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.34 by $0.04. The business had revenue of $4.09 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.42 earnings per share. On average, research analysts expect that Allergan plc will post 16.68 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th were issued a $0.74 dividend. The ex-dividend date was Monday, August 12th. This represents a $2.96 annualized dividend and a yield of 1.75%. Allergan’s dividend payout ratio (DPR) is presently 17.74%.

Several research firms recently commented on AGN. Wells Fargo & Co reissued an “outperform” rating and set a $184.00 price objective (up previously from $176.00) on shares of Allergan in a research note on Monday, September 30th. ValuEngine raised shares of Allergan from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. SunTrust Banks boosted their price objective on shares of Allergan to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a research note on Friday, July 12th. Finally, Guggenheim lowered shares of Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $179.15.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Read More: Do Tariffs Work?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.